Figure 1.
Oncoprint of mutations in gilteritinib treated patients pre- and post-treatment. Row 1 indicates the transplant status of the patient; relapsed/refractory pre-bone marrow transplant (BMT) or post-BMT. Row 2 shows progression of treatment with green indicating pre-treatment samples and yellow indicating post initiation with an increasing gradient showing progression of treatment. Row 3 displays scRNASeq samples. Row 4 designates the FLT3 status. The patient ID is indicated below each column. Each remaining row represents genes mutated with a variant allele frequency (VAF) cut-off of 0.05. Blue indicates present, red is new/emerging, white is absent and lavender is not available.

Oncoprint of mutations in gilteritinib treated patients pre- and post-treatment. Row 1 indicates the transplant status of the patient; relapsed/refractory pre-bone marrow transplant (BMT) or post-BMT. Row 2 shows progression of treatment with green indicating pre-treatment samples and yellow indicating post initiation with an increasing gradient showing progression of treatment. Row 3 displays scRNASeq samples. Row 4 designates the FLT3 status. The patient ID is indicated below each column. Each remaining row represents genes mutated with a variant allele frequency (VAF) cut-off of 0.05. Blue indicates present, red is new/emerging, white is absent and lavender is not available.

Close Modal

or Create an Account

Close Modal
Close Modal